My own personal opinion is I'm holding at least till 2020. I think Art is to smart to let this fail. Instead of building up cash flow and squirreling it away, he's expanding our reachable patrons of the drugs. patiently he has been adding more generics to the flow, (with no action from analyst). If any of my other holdings shows a slight uptick, I will purchase more Anip.
News 
Market Data 
Discover 
